Previous Next

CURRENT ISSUE

№2' 2020

INFECTIOUS DISEASES

International Medical Journal, Vol. 26., Iss. 2, 2020, P. 66−69.


DOI (https://doi.org/10.37436/2308-5274-2020-2-13)

"CLARITHROMYCIN-MB" CLINICAL EFFICACY IN COMBINED THERAPY OF PATIENTS WITH COMMUNITY-ACQUIRED PNEUMONIA


Liadova T. I., Volobuieva O. V., Shepylieva N. V., Pavlov V. V., Sevastianova T. V., Shevchenko O. O., Volobuiev D. O.

V. N. Karazin Kharkiv National University, Ukraine

The problem of rational antibiotic therapy of pneumonia is one of the most relevant in modern medicine. So far, a large number of the factors have been identified that determine the optimal quality of antimicrobial therapy: the maximum effectiveness with the lowest toxicity of drugs should be combined with their proper cost. In order to study the clinical efficacy and therapeutic tolerability of the drug class of macrolides, clarithromycin for parenteral use in the treatment of patients with community−acquired pneumonia, 20 patients were examined. All the patients had clinical symptoms of severe infectious lesions of the lower respiratory tract. The complex therapy (detoxification, mucolytic drugs, multivitamins, metabolites) included "Clarithromycin−MB", which was administered intravenously for 60 minutes at a dose of 500 mg 2 times a day for 7−10 days. The clinical effectiveness of antibacterial therapy was assessed by the dynamics of the activity of the inflammatory process in the lungs. For this purpose, the following clinical and laboratory parameters characterizing the activity of the inflammatory process (temperature response, tachycardia, respiratory rate, leukocytosis, number of immature granulocytes, change in erythrocyte sedimentation rate), severity of pain, radiological changes in the lungs were determined. Macrolide "Clarithromycin−MB" in a parenteral form is a highly effective antibacterial drug for the treatment of community−acquired pneumonia with severe course. Positive dynamics of clinical manifestations of the disease was observed on the third day from the beginning of therapy. "Clarithromycin−MB" has good therapeutic tolerability, the dosage regimen allows to maintain the required concentration in the site of inflammation, which affects the clinical and bacteriological efficacy of treatment of the patients with community−acquired pneumonia.

Key words: community−acquired pneumonia, macrolides, "Clarithromycin−MB".


REFERENCES


1. Shikhnebiev D. A. Sovremennye podkhody k antimikrobnoi terapii vnegospital'nykh pnevmonii (obzor literatury) // Mezhdunar. zhurn. prikladnykh i fundamental'nykh issledovanii. 2014. № 4. S. 101−104.

2. Protokol nadannya medichnoї dopomogi khvorim na negospіtal'nu ta nozokomіal'nu (gospіtal'nu) pnevmonіyu u doroslikh osіb: etіologіya, patogenez, klasifіkatsіya, dіagnostika, antibakterіal'na terapіya: Nakaz MOZ Ukraїni vіd 19.03. 2007 r. № 128. URL: ifp.kiev.ua/doc/staff/MOZ−128−19032007pdf

3. Negospіtal'na pnevmonіya u doroslikh osіb: etіologіya, patogenez, klasifіkatsіya, dіagnostika, antibakterіal'na terapіya (proekt klіnіchnikh nastanov). Chastina ІІ / Yu. І. Feshchenko ta іn. // Ukr. pul'monologіchnii zhurn. 2013. № 1. S. 5−21.

4. Antimicrobial resistance trends among sinus isolates of Streptococcus pneumoniae in the United States (2001−2005) / D. F. Sahm et al. // Otolaryngol. Head Neck Surg. 2007. Vol. 136 (3). P. 385−389. doi: https://doi.org/10.1016/j.otohns.2006.09.016

5. Strachunskii L. S., Kozlov S. N. Makrolidy v sovremennoi klinicheskoi praktike // Klinicheskaya meditsina. 2012. № 3. S. 23−30.

6. Antimicrobial Chemotherapy / D. Greenwood, R. Finch, P. Davey, M. Wilcox // Oxford. 1995. Vol. 4. P. 43−49.

7. Labro M. T. Antibiotics as anti−inflammatory drugs // Current Opinion in Investigational Drugs. 2002. Vol. 3. P. 61−68.

8. A new macrolide, TE−031 (A−56268), in treatment of experimental Legionnais' disease / S. Kohno et al. // J. Antimicrob. Chemother. 1989. Vol. 24. P. 397−405. doi: https://doi.org/10.1093/jac/24.3.397

9. Long−term administration study on TE−031 (A−56268) in treatment of diffuse panbronchiolitis / H. Takeda et al. // Kansenshodaku Zasshi. 1989. Vol. 63. P. 71−78.

10. Pro−versus anti−inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options / C. A. Gogos, E. Drosou, H. P. Bassaris, A. Skoutelis // J. Infect. Dis. 2000. Vol. 181. P. 176−180. doi: https://doi.org/10.1086/315214

11. Effect of clarithromycin in patients with sepsis and ventilator−associated pneumonia / E. J. GiamarellosBourboulis et al. // Clin. Infect. Dis. 2008. Vol. 46 (8). P. 1157−1164. doi: 10.1086/529439

12. Aver'yanov A. V., Zykov K. A. Klaritromitsin v lechenii obostrenii khronicheskoi obstruktivnoi bolezni legkikh // Ukr. pul'monol. zhurn. 2009. № 2. S. 48−52.

Go on Top